BU

BUKWANG PHARMACEUTICAL IND CO.,LTD

R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.

003000 | KO

Overview

Corporate Details

ISIN(s):
KR7003000007
LEI:
Country:
South Korea
Address:
서울특별시 동작구 대방동1길 47, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bukwang Pharmaceutical Co., Ltd. is an R&D-focused pharmaceutical company engaged in the development, manufacturing, and commercialization of therapeutic drugs. The company employs an 'open innovation' strategy, utilizing strategic investments, joint ventures, research collaborations, and acquisitions to expand its drug pipeline and enhance its global competitiveness. Its development pipeline targets a range of conditions, with a focus on central nervous system (CNS) disorders such as schizophrenia (Lurasidone) and Parkinson's disease (JM-010), as well as oncology (SOL-804 for prostate cancer), liver diseases, and metabolic disorders. Through continuous research and strategic partnerships, Bukwang aims to become a global pharmaceutical innovator.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-07-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.4 KB
2025-07-22 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 20.8 KB
2025-07-21 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 21.2 KB
2025-07-16 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 196.6 KB
2025-07-16 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
Korean 8.5 KB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-07-15 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 11.3 KB
2025-07-15 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.3 KB
2025-07-10 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시)
Korean 12.1 KB
2025-07-10 00:00
Related Party Transaction
[기재정정]특수관계인의유상증자참여
Korean 12.9 KB

Automate Your Workflow. Get a real-time feed of all BUKWANG PHARMACEUTICAL IND CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BUKWANG PHARMACEUTICAL IND CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BUKWANG PHARMACEUTICAL IND CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.